July 16, 2019
Trefoil Therapeutics Raises $28 Million Series A to Advance Engineered FGF-1 for the Treatment of Corneal Diseases
Lead candidate TTHX1114 will advance to IND and clinical study in corneal endothelial disease in early 2020
San Diego, California. Trefoil Therapeutics announced it raised $28 million in an oversubscribed Series A financing. The company is developing novel engineered fibroblast growth factor-1 proteins (eFGF-1) as a regenerative pharmacologic therapy to treat serious corneal endothelial diseases and epithelial disorders. The financing included new investors Bios Partners, which led the round, and Access Biotechnology. All existing investors, including Hatteras Venture Partners, Aju IB Investment, Correlation Ventures, ExSight Ventures and InFocus Capital Partners, participated in this financing. Stella M. Robertson, Ph.D., co-founder of Bios Partners, and a former vice president in Research & Development at Alcon Laboratories, will join Trefoil’s Board of Directors.